- NEWS AND VIEWS
New antifungal breaks the mould
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 640, 606-607 (2025)
doi: https://doi.org/10.1038/d41586-025-00801-0
References
Lee, Y., Robbins, N. & Cowen, L. E. npj Antimicrob. Resist. 1, 5 (2023).
Vosseberg, J. et al. Nature 633, 295–305 (2024).
Turchin, P. et al. PLoS ONE 16, e0258161 (2021).
Deveau, A. et al. FEMS Microbiol. Rev. 42, 335–352 (2018).
Deng, Q. et al. Nature 640, 743–751 (2025).
Gray, K. C. et al. Proc. Natl Acad. Sci. USA 109, 2234–2239 (2012).
Anderson, T. M. et al. Nature Chem. Biol. 10, 400–406 (2014).
Maji, A. et al. Nature 623, 1079–1085 (2023).
Guo, X. et al. ACS Cent. Sci. 7, 781–791 (2021).
Ju, K. S. et al. Proc. Natl Acad. Sci. USA 112, 12175–12180 (2015).
Culp, E. J. et al. Nature 578, 582–587 (2020).
Competing Interests
A.M. and M.D.B. are inventors on patent applications related to glycosylated macrolide antifungals, including AM-2-19/SF001. M.D.B. is a shareholder for Sfunga Therapeutics (now Elion Therapeutics), which has licensed these patent applications from the University of Illinois.
Read the paper: A polyene macrolide targeting phospholipids in the fungal cell membrane
Mini saunas save endangered frogs from fungal disease
Synthetic drug kills fungi but spares kidney cells